These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 1336052)
21. Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. Shen TY; Hwang SB; Chang MN; Doebber TW; Lam MH; Wu MS; Wang X; Han GQ; Li RZ Proc Natl Acad Sci U S A; 1985 Feb; 82(3):672-6. PubMed ID: 2983307 [TBL] [Abstract][Full Text] [Related]
22. [Effect of analogs and antagonists of the thrombocyte-activating factor (PAF) on blood platelet aggregation]. Lakin KM; Kulikov VI; Manevich EM; Muliar AG; Shvets VI Farmakol Toksikol; 1988; 51(4):113-23. PubMed ID: 2847936 [No Abstract] [Full Text] [Related]
23. 4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists. Sunkel CE; de Casa-Juana MF; Santos L; Gómez MM; Villarroya M; González-Morales MA; Priego JG; Ortega MP J Med Chem; 1990 Dec; 33(12):3205-10. PubMed ID: 2175357 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of human platelet aggregation by amides and ester of salicylic acid with platelet-activating factor analogs. Kulikov VI; Muzya GI Biochemistry (Mosc); 2001 Jun; 66(6):658-61. PubMed ID: 11421815 [TBL] [Abstract][Full Text] [Related]
25. A specific, photolabile and irreversible antagonist (L662,025) of the PAF-receptor. Hussaini IM; Shen TY Biochem Biophys Res Commun; 1989 May; 161(1):23-30. PubMed ID: 2543410 [TBL] [Abstract][Full Text] [Related]
26. Characterization of receptors for platelet-activating factor on platelets, polymorphonuclear leukocytes and macrophages. Stewart AG; Dusting GJ Br J Pharmacol; 1988 Aug; 94(4):1225-33. PubMed ID: 2850058 [TBL] [Abstract][Full Text] [Related]
27. Platelet-activating factor stimulation of tyrosine kinase and its relationship to phospholipase C in rabbit platelets: studies with genistein and monoclonal antibody to phosphotyrosine. Dhar A; Paul AK; Shukla SD Mol Pharmacol; 1990 Apr; 37(4):519-25. PubMed ID: 1691437 [TBL] [Abstract][Full Text] [Related]
28. The isolation and characterization of kadsurenone from haifenteng (Piper futokadsura) as an orally active specific receptor antagonist of platelet-activating factor. Shen TY; Hwang SB; Chang MN; Doebber TW; Lam MH; Wu MS; Wang X Int J Tissue React; 1985; 7(5):339-43. PubMed ID: 2997065 [TBL] [Abstract][Full Text] [Related]
29. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets. Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712 [TBL] [Abstract][Full Text] [Related]
30. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils. Koike H; Imanishi N; Natsume Y; Morooka S Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770 [TBL] [Abstract][Full Text] [Related]
31. Prehispanolone, a novel platelet activating factor receptor antagonist from Leonurus heterophyllus. Lee CM; Jiang LM; Shang HS; Hon PM; He Y; Wong HN Br J Pharmacol; 1991 Jul; 103(3):1719-24. PubMed ID: 1657264 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba. Lamant V; Mauco G; Braquet P; Chap H; Douste-Blazy L Biochem Pharmacol; 1987 Sep; 36(17):2749-52. PubMed ID: 2820421 [TBL] [Abstract][Full Text] [Related]
34. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action. Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772 [TBL] [Abstract][Full Text] [Related]
35. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor. Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449 [TBL] [Abstract][Full Text] [Related]
36. The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB2086. Griffin K; Hong T; Levy JV Biochem Biophys Res Commun; 1989 Apr; 160(1):263-7. PubMed ID: 2540748 [TBL] [Abstract][Full Text] [Related]
37. PAF-receptor. III. Conformational and electronic properties of PAF-like agonists and antagonists. Lamotte-Brasseur J; Dive G; Lamouri A; Heymans F; Godfroid JJ Biochim Biophys Acta; 1991 Aug; 1085(1):91-105. PubMed ID: 1654112 [TBL] [Abstract][Full Text] [Related]
38. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models. Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352 [TBL] [Abstract][Full Text] [Related]